Danske Bank cuts target for Coloplast stock to DKK 435.00

Published on 10/13/2026 at 01:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coloplast reported 6.00 percent organic growth in the third quarter. For Coloplast stock this means 5.00 percent EBIT growth in fiscal 2025/26.

Key points in brief

Danske Bank cut its Coloplast target from DKK 470.00 to DKK 435.00 on October 7, 2026.
Coloplast reported 6.00 percent organic growth in the first nine months of fiscal 2025/26.
The last Lang & Schwarz indication was EUR 59.56 on October 12, 2026, while Nasdaq Copenhagen showed DKK 446.30.
Fiscal 2025/26 guidance calls for 5.00-6.00 percent organic revenue growth and 5.00 percent EBIT growth.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin am Mikroskop im Forschungslabor — Coloplast A/S (DK0060448595) inspiriert diese dokumentarische Schwarzweiß-Aufnahme eines konzentrierten Forschungslabors mit Wissenschaftlerin am Mikroskop, Illustration mit AI erstellt.

Danske Bank cut its Coloplast target from DKK 470.00 to DKK 435.00 on October 7, 2026, while retaining a Hold rating, according to Affärsvärlden. The reduction followed a similar Barclays cut from DKK 495.00 to DKK 465.00 on October 6, 2026.

Three targets moved lower

On August 18, 2026, Coloplast reported DKK 21.482 billion of revenue for the first nine months of fiscal 2025/26, up 3.00 percent from the prior-year period, according to GlobeNewswire. Organic growth was 6.00 percent, but reported EBIT before special items fell 2.00 percent to DKK 5.599 billion.

On October 6, 2026, Barclays lowered its target from DKK 495.00 to DKK 465.00 and kept an Equal Weight view, according to Zonebourse. On October 7, Danske Bank followed with its DKK 35.00 reduction, leaving the target below the October 12 Nasdaq Copenhagen quote.

What does guidance mean?

Coloplast kept fiscal 2025/26 guidance at 5.00-6.00 percent organic revenue growth and 5.00 percent EBIT growth in constant currencies. The company also expects a 26.00 percent EBIT margin before special items for the first nine months, compared with 27.00 percent a year earlier.

The operating picture is mixed by segment. Continence Care delivered 8.00 percent organic growth in the third quarter, while Biologics revenue fell 6.00 percent because of reimbursement-related challenges, according to GlobeNewswire in the August 18, 2026 report.

Next dates and market levels

Affärsvärlden lists November 3, 2026 as Coloplast's annual report date and February 9, 2027 as the next interim report date. The dates give the revised analyst targets two scheduled company checkpoints.

The last Lang & Schwarz indication was EUR 59.56 on October 12, 2026 at 11:00 p.m. CEST. On Nasdaq Copenhagen, Coloplast traded at DKK 446.30 on October 12, 2026 at 4:59 p.m. CEST, against a 52-week range of DKK 369.70 to DKK 631.40.real-time quote of Coloplast stock.